EAM
NTLA icon

EFG Asset Management’s Intellia Therapeutics NTLA Stock Holding History

EFG Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,316
Closed -$690K – 193
2022
Q2 		$690K Sell
13,316
-1,142
-8% -$58K 0.15% 169
2022
Q1 		$1.05M Buy
+14,458
New +$1.22M 0.16% 165

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EFG Asset Management's NTLA Position: Q3 2022 in Review

EFG Asset Management sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 13,316 shares — an estimated $690K sold.

EFG Asset Management first reported a position in NTLA in Q1 2022 and held it in 2 quarters. The position peaked at $1.05M in Q1 2022. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • EFG Asset Management reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • EFG Asset Management sold 13,316 Intellia Therapeutics shares in Q3 2022, an estimated $690K.
  • EFG Asset Management first reported a position in Intellia Therapeutics in Q1 2022 and held it in 2 quarters.
  • EFG Asset Management's Intellia Therapeutics position peaked at $1.05M in Q1 2022.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on EFG Asset Management's 13F filing for Q3 2022, filed 28 Oct 2022.